Stock Events

Stock Events

Diamyd Medical AB 

$0.7300
1
-$0.00-0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
0.73
52W Low
0.73
Volume
-
Avg. Volume
0
Mkt Cap
97.82M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

31AugExpected
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
-0.06
0.02
0.1
0.18
Expected EPS
0
Actual EPS
-0.0441

Financials

-130,231.69%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
13,398.53Revenue
-17.45MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DYMDF. It's not an investment recommendation.
Xbrane Biopharma AB
2
XBRANE.ST

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap201.05B
Novo Nordisk is a leading global healthcare company that focuses on diabetes care, directly competing with Diamyd Medical's diabetes treatment and vaccine development.
Sanofi
SNY
Mkt Cap104.76B
Sanofi is involved in the research, development, and marketing of therapeutic solutions including diabetes management, making it a competitor in the diabetes care market.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly is a major player in the pharmaceutical industry with a strong focus on diabetes care and insulin production, competing in the same space as Diamyd Medical.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. offers a range of diabetes treatments and management solutions, positioning it as a competitor in the diabetes healthcare sector.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca operates in various therapeutic areas, including diabetes, where it competes with Diamyd Medical through its portfolio of diabetes medications.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol-Myers Squibb has a presence in the diabetes care market through its development of diabetes treatments, making it a competitor.
Tandem Diabetes Care
TNDM
Mkt Cap1.58B
Tandem Diabetes Care, Inc. specializes in insulin delivery systems, competing in the diabetes management space with innovative technology solutions.
Insulet
PODD
Mkt Cap9.94B
Insulet Corporation is known for its Omnipod Insulin Management System, competing in the diabetes care market with a focus on insulin delivery technologies.
Dexcom
DXCM
Mkt Cap33.87B
DexCom, Inc. provides continuous glucose monitoring systems for diabetes management, directly competing in the diabetes care technology market.
Medicinova
MNOV
Mkt Cap64.48M
MediciNova, Inc. is involved in the development of therapeutic products for diseases with unmet medical needs, including diabetes, positioning it as a competitor in the broader diabetes treatment market.

About

Diamyd Medical AB (publ), a Swedish company founded in Stockholm in 1984, specializes in developing innovative treatments for autoimmune diabetes. Formerly known as Diamyd Therapeutics AB until its name change in April 2013, the company is advancing two key therapeutic candidates. Its flagship product, Diamyd, is an antigen-specific immunotherapy vaccine for diabetes currently undergoing Phase IIb clinical studies for both type 1 diabetes and latent autoimmune diabetes. Additionally, Remygen, an oral drug candidate with regenerative and immunomodulatory properties, is progressing through Phase I/II clinical trials for the treatment of autoimmune and type 2 diabetes.
Show more...
CEO
Mr. Ulf Hannelius
Employees
44
Country
United States
ISIN
SE0005162880
WKN
000A1T90L

Listings

ST
SE
DMYD-BTU-B.ST
ST
SE
DMYD-B.ST
Grey Market
US
DYMDF
MU
DE
DMN.MU

0 Comments

Share your thoughts

FAQ

What is Diamyd Medical AB stock price today?▼
The current price of DYMDF is $0.73 USD — it has decreased by -0% in the past 24 hours. Watch Diamyd Medical AB stock price performance more closely on the chart.
What is Diamyd Medical AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Grey Market exchange Diamyd Medical AB stocks are traded under the ticker DYMDF.
Is Diamyd Medical AB stock price growing?▼
DYMDF stock has risen by +0% compared to the previous week, the month change is a -0% fall, over the last year Diamyd Medical AB has showed a -0% decrease.
What is Diamyd Medical AB market cap?▼
Today Diamyd Medical AB has the market capitalization of 97.82M
What were Diamyd Medical AB earnings last quarter?▼
DYMDF earnings for the last quarter are -0.04 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Diamyd Medical AB revenue for the last year?▼
Diamyd Medical AB revenue for the last year amounts to 13,398.53 USD.
What is Diamyd Medical AB net income for the last year?▼
DYMDF net income for the last year is -17.45M USD.
How many employees does Diamyd Medical AB have?▼
As of August 22, 2026, the company has 44 employees.
In which sector is Diamyd Medical AB located?▼
Diamyd Medical AB operates in the Other sector.
When did Diamyd Medical AB complete a stock split?▼
Diamyd Medical AB has not had any recent stock splits.
Where is Diamyd Medical AB headquartered?▼
Diamyd Medical AB is headquartered in Stockholm, United States.